Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Total Current Liabilities (2020 - 2025)

Pulse Biosciences has reported Total Current Liabilities over the past 6 years, most recently at $9.7 million for Q3 2025.

  • Quarterly results put Total Current Liabilities at $9.7 million for Q3 2025, up 43.9% from a year ago — trailing twelve months through Sep 2025 was $9.7 million (up 43.9% YoY), and the annual figure for FY2024 was $10.1 million, up 49.9%.
  • Total Current Liabilities for Q3 2025 was $9.7 million at Pulse Biosciences, up from $9.0 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for PLSE hit a ceiling of $10.1 million in Q4 2024 and a floor of $5.1 million in Q1 2024.
  • Median Total Current Liabilities over the past 5 years was $7.0 million (2022), compared with a mean of $7.5 million.
  • Biggest five-year swings in Total Current Liabilities: soared 152.08% in 2021 and later dropped 27.32% in 2024.
  • Pulse Biosciences' Total Current Liabilities stood at $6.7 million in 2021, then decreased by 10.84% to $6.0 million in 2022, then grew by 12.16% to $6.7 million in 2023, then skyrocketed by 49.9% to $10.1 million in 2024, then decreased by 3.53% to $9.7 million in 2025.
  • The last three reported values for Total Current Liabilities were $9.7 million (Q3 2025), $9.0 million (Q2 2025), and $7.8 million (Q1 2025) per Business Quant data.